Cardio Diagnostics Holdings, Inc.
corporate_fare Company Profile
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for CDIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for CDIO spans 10-Q, PRE 14A, 10-K, 8-K.
Recent high-impact activity:
- Cardio Diagnostics Posts $1.73M Q3 Loss; Cash at $3.94M as Material Weakness and Nasdaq MVLS Risk Persist
- Cardio Diagnostics Q2: Material Weakness, Nasdaq Delisting Risk, and $1.5M Loss on $5K Revenue
- Cardio Diagnostics Seeks Stockholder Nod for Up to $10M Dilutive Issuance at 2026 Annual Meeting
- Cardio Diagnostics Secures Coverage for Precision Heart Tests with Atlas Healthcare Physicians
- Cardio Diagnostics Reports $1.79M Net Loss on Just $2.68K Revenue in Q1
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 4,836 shares in CDIO as of the October 30, 2026 settlement, a 62.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 10.2% of CDIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CDIO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-13.
2026 Issuance Proposal · Potential Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →